nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—Tonsillitis—Metformin—polycystic ovary syndrome	0.0323	0.154	CcSEcCtD
Pimecrolimus—MTOR—embryo—polycystic ovary syndrome	0.0168	0.0822	CbGeAlD
Pimecrolimus—Sinus congestion—Metformin—polycystic ovary syndrome	0.0164	0.0784	CcSEcCtD
Pimecrolimus—CYP3A4—urine—polycystic ovary syndrome	0.0153	0.0747	CbGeAlD
Pimecrolimus—Loose stools—Metformin—polycystic ovary syndrome	0.0148	0.0705	CcSEcCtD
Pimecrolimus—Toothache—Metformin—polycystic ovary syndrome	0.0134	0.0641	CcSEcCtD
Pimecrolimus—FKBP1A—adrenal cortex—polycystic ovary syndrome	0.0124	0.0606	CbGeAlD
Pimecrolimus—MTOR—endometrium—polycystic ovary syndrome	0.0123	0.0602	CbGeAlD
Pimecrolimus—MTOR—uterus—polycystic ovary syndrome	0.0113	0.0554	CbGeAlD
Pimecrolimus—MTOR—pituitary gland—polycystic ovary syndrome	0.0111	0.0544	CbGeAlD
Pimecrolimus—MTOR—adipose tissue—polycystic ovary syndrome	0.0111	0.0542	CbGeAlD
Pimecrolimus—FKBP1A—endometrium—polycystic ovary syndrome	0.0111	0.0541	CbGeAlD
Pimecrolimus—FKBP1A—uterus—polycystic ovary syndrome	0.0102	0.0499	CbGeAlD
Pimecrolimus—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.0101	0.0482	CcSEcCtD
Pimecrolimus—FKBP1A—pituitary gland—polycystic ovary syndrome	0.01	0.049	CbGeAlD
Pimecrolimus—FKBP1A—adipose tissue—polycystic ovary syndrome	0.00997	0.0488	CbGeAlD
Pimecrolimus—MTOR—adrenal gland—polycystic ovary syndrome	0.00995	0.0486	CbGeAlD
Pimecrolimus—MTOR—female gonad—polycystic ovary syndrome	0.00927	0.0453	CbGeAlD
Pimecrolimus—MTOR—vagina—polycystic ovary syndrome	0.00922	0.0451	CbGeAlD
Pimecrolimus—FKBP1A—adrenal gland—polycystic ovary syndrome	0.00895	0.0437	CbGeAlD
Pimecrolimus—MTOR—endocrine gland—polycystic ovary syndrome	0.00863	0.0422	CbGeAlD
Pimecrolimus—FKBP1A—female gonad—polycystic ovary syndrome	0.00834	0.0408	CbGeAlD
Pimecrolimus—FKBP1A—vagina—polycystic ovary syndrome	0.00829	0.0405	CbGeAlD
Pimecrolimus—FKBP1A—endocrine gland—polycystic ovary syndrome	0.00776	0.0379	CbGeAlD
Pimecrolimus—Ear pain—Metformin—polycystic ovary syndrome	0.00695	0.0332	CcSEcCtD
Pimecrolimus—Nasal congestion—Metformin—polycystic ovary syndrome	0.00651	0.0311	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00542	0.0259	CcSEcCtD
Pimecrolimus—Breast disorder—Metformin—polycystic ovary syndrome	0.00536	0.0256	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.0053	0.0253	CcSEcCtD
Pimecrolimus—Influenza—Metformin—polycystic ovary syndrome	0.00513	0.0245	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00476	0.0227	CcSEcCtD
Pimecrolimus—Infestation NOS—Metformin—polycystic ovary syndrome	0.00457	0.0218	CcSEcCtD
Pimecrolimus—Infestation—Metformin—polycystic ovary syndrome	0.00457	0.0218	CcSEcCtD
Pimecrolimus—Rhinitis—Metformin—polycystic ovary syndrome	0.00411	0.0196	CcSEcCtD
Pimecrolimus—Eye disorder—Metformin—polycystic ovary syndrome	0.00383	0.0183	CcSEcCtD
Pimecrolimus—Flushing—Metformin—polycystic ovary syndrome	0.00381	0.0182	CcSEcCtD
Pimecrolimus—Immune system disorder—Metformin—polycystic ovary syndrome	0.00371	0.0177	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.0037	0.0177	CcSEcCtD
Pimecrolimus—Malnutrition—Metformin—polycystic ovary syndrome	0.00357	0.0171	CcSEcCtD
Pimecrolimus—Erythema—Metformin—polycystic ovary syndrome	0.00357	0.0171	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00302	0.0144	CcSEcCtD
Pimecrolimus—Oedema—Metformin—polycystic ovary syndrome	0.00291	0.0139	CcSEcCtD
Pimecrolimus—Infection—Metformin—polycystic ovary syndrome	0.0029	0.0138	CcSEcCtD
Pimecrolimus—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00286	0.0136	CcSEcCtD
Pimecrolimus—Skin disorder—Metformin—polycystic ovary syndrome	0.00283	0.0135	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00266	0.0127	CcSEcCtD
Pimecrolimus—Paraesthesia—Metformin—polycystic ovary syndrome	0.00262	0.0125	CcSEcCtD
Pimecrolimus—Dyspnoea—Metformin—polycystic ovary syndrome	0.0026	0.0124	CcSEcCtD
Pimecrolimus—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00254	0.0124	CbGeAlD
Pimecrolimus—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00252	0.012	CcSEcCtD
Pimecrolimus—Constipation—Metformin—polycystic ovary syndrome	0.00249	0.0119	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00238	0.0114	CcSEcCtD
Pimecrolimus—Urticaria—Metformin—polycystic ovary syndrome	0.00232	0.0111	CcSEcCtD
Pimecrolimus—Abdominal pain—Metformin—polycystic ovary syndrome	0.0023	0.011	CcSEcCtD
Pimecrolimus—Pruritus—Metformin—polycystic ovary syndrome	0.00206	0.00985	CcSEcCtD
Pimecrolimus—Diarrhoea—Metformin—polycystic ovary syndrome	0.00199	0.00952	CcSEcCtD
Pimecrolimus—Vomiting—Metformin—polycystic ovary syndrome	0.00185	0.00885	CcSEcCtD
Pimecrolimus—Rash—Metformin—polycystic ovary syndrome	0.00184	0.00878	CcSEcCtD
Pimecrolimus—Dermatitis—Metformin—polycystic ovary syndrome	0.00184	0.00877	CcSEcCtD
Pimecrolimus—Headache—Metformin—polycystic ovary syndrome	0.00183	0.00872	CcSEcCtD
Pimecrolimus—Nausea—Metformin—polycystic ovary syndrome	0.00173	0.00827	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—IRS1—polycystic ovary syndrome	0.000394	0.000672	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGF18—polycystic ovary syndrome	0.000394	0.000672	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGF18—polycystic ovary syndrome	0.000392	0.000669	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—BCL2—polycystic ovary syndrome	0.000391	0.000667	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT2—polycystic ovary syndrome	0.00039	0.000666	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—RBP4—polycystic ovary syndrome	0.000389	0.000663	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NRG1—polycystic ovary syndrome	0.000388	0.000662	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT2—polycystic ovary syndrome	0.000387	0.00066	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT2—polycystic ovary syndrome	0.000385	0.000658	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—polycystic ovary syndrome	0.000385	0.000657	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FLT4—polycystic ovary syndrome	0.000378	0.000646	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IRS1—polycystic ovary syndrome	0.000377	0.000643	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—GAB1—polycystic ovary syndrome	0.000374	0.000639	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—AKT2—polycystic ovary syndrome	0.000365	0.000622	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—VEGFA—polycystic ovary syndrome	0.000364	0.000621	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—GAB1—polycystic ovary syndrome	0.00036	0.000614	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000359	0.000613	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—GAB1—polycystic ovary syndrome	0.000358	0.000611	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT2—polycystic ovary syndrome	0.000349	0.000595	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NAMPT—polycystic ovary syndrome	0.000349	0.000595	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.000348	0.000595	CbGpPWpGaD
Pimecrolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.000346	0.000591	CbGpPWpGaD
Pimecrolimus—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.000342	0.000583	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000338	0.000576	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TNRC6B—polycystic ovary syndrome	0.000335	0.000571	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IRS2—polycystic ovary syndrome	0.000332	0.000567	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NPB—polycystic ovary syndrome	0.000331	0.000564	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000329	0.000561	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKR1C3—polycystic ovary syndrome	0.000325	0.000555	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—TNRC6B—polycystic ovary syndrome	0.000322	0.000549	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—polycystic ovary syndrome	0.00032	0.000547	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FST—polycystic ovary syndrome	0.00032	0.000546	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TNRC6B—polycystic ovary syndrome	0.00032	0.000546	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000316	0.00054	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—LHB—polycystic ovary syndrome	0.000313	0.000533	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—IL6—polycystic ovary syndrome	0.000312	0.000532	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—polycystic ovary syndrome	0.000309	0.000527	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000305	0.000521	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.000304	0.000519	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RPL37A—polycystic ovary syndrome	0.000304	0.000519	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—polycystic ovary syndrome	0.000301	0.000513	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—polycystic ovary syndrome	0.000301	0.000513	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.000299	0.00051	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000296	0.000505	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ATF1—polycystic ovary syndrome	0.000294	0.000502	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RACGAP1—polycystic ovary syndrome	0.000294	0.000501	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SCT—polycystic ovary syndrome	0.000293	0.0005	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—polycystic ovary syndrome	0.000292	0.000499	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IRS1—polycystic ovary syndrome	0.00029	0.000495	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HMMR—polycystic ovary syndrome	0.000289	0.000492	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.000284	0.000485	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.000281	0.000479	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.00028	0.000478	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000279	0.000477	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000276	0.000471	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000276	0.000471	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000275	0.000469	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TCF7L2—polycystic ovary syndrome	0.000274	0.000468	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000272	0.000465	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TAB1—polycystic ovary syndrome	0.000271	0.000463	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—polycystic ovary syndrome	0.00027	0.000462	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SLC2A4—polycystic ovary syndrome	0.00027	0.00046	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT2—polycystic ovary syndrome	0.000268	0.000458	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—polycystic ovary syndrome	0.000266	0.000455	CbGpPWpGaD
Pimecrolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	0.000258	0.000441	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000258	0.000441	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PRL—polycystic ovary syndrome	0.000257	0.000439	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000254	0.000434	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP11A1—polycystic ovary syndrome	0.000252	0.000429	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—polycystic ovary syndrome	0.000251	0.000429	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000251	0.000428	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000251	0.000428	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—polycystic ovary syndrome	0.00025	0.000426	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	0.000248	0.000423	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000244	0.000416	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—INSR—polycystic ovary syndrome	0.00024	0.000409	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF18—polycystic ovary syndrome	0.000239	0.000408	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000238	0.000406	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKR1C1—polycystic ovary syndrome	0.000238	0.000405	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	0.000234	0.0004	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP17A1—polycystic ovary syndrome	0.000234	0.000399	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	0.000231	0.000394	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000228	0.000389	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000224	0.000383	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PGR—polycystic ovary syndrome	0.000222	0.000379	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000222	0.000379	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRG1—polycystic ovary syndrome	0.000221	0.000377	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF18—polycystic ovary syndrome	0.000221	0.000376	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RBP4—polycystic ovary syndrome	0.000219	0.000373	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—GAB1—polycystic ovary syndrome	0.000218	0.000372	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NCOR1—polycystic ovary syndrome	0.000215	0.000368	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—polycystic ovary syndrome	0.000214	0.000365	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRG1—polycystic ovary syndrome	0.000212	0.000362	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRG1—polycystic ovary syndrome	0.000211	0.000361	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	0.000209	0.000357	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000206	0.000352	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000206	0.000352	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—polycystic ovary syndrome	0.000204	0.000349	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000202	0.000345	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—GAB1—polycystic ovary syndrome	0.000201	0.000344	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—polycystic ovary syndrome	0.000201	0.000343	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CAMK2D—polycystic ovary syndrome	0.000198	0.000338	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000197	0.000336	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NAMPT—polycystic ovary syndrome	0.000196	0.000335	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TNRC6B—polycystic ovary syndrome	0.000195	0.000333	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—polycystic ovary syndrome	0.000192	0.000328	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000192	0.000328	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—polycystic ovary syndrome	0.000191	0.000326	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTHFR—polycystic ovary syndrome	0.00019	0.000325	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—polycystic ovary syndrome	0.00019	0.000325	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.00019	0.000324	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IRS2—polycystic ovary syndrome	0.000189	0.000323	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CRP—polycystic ovary syndrome	0.000189	0.000323	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—polycystic ovary syndrome	0.000189	0.000323	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—polycystic ovary syndrome	0.000187	0.000319	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.000185	0.000316	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000185	0.000315	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKR1C3—polycystic ovary syndrome	0.000183	0.000312	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	0.000183	0.000312	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—IRS2—polycystic ovary syndrome	0.000182	0.00031	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000182	0.00031	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IRS2—polycystic ovary syndrome	0.000181	0.000309	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FST—polycystic ovary syndrome	0.00018	0.000307	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TNRC6B—polycystic ovary syndrome	0.00018	0.000307	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PRL—polycystic ovary syndrome	0.00018	0.000307	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—polycystic ovary syndrome	0.000178	0.000304	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—polycystic ovary syndrome	0.000178	0.000304	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—polycystic ovary syndrome	0.000178	0.000304	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000178	0.000304	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—polycystic ovary syndrome	0.000177	0.000301	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LHB—polycystic ovary syndrome	0.000176	0.0003	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—polycystic ovary syndrome	0.000175	0.000299	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—polycystic ovary syndrome	0.000174	0.000297	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000172	0.000293	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ATF1—polycystic ovary syndrome	0.000171	0.000292	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000171	0.000291	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000166	0.000284	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IRS1—polycystic ovary syndrome	0.000165	0.000282	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SCT—polycystic ovary syndrome	0.000165	0.000281	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—IRS1—polycystic ovary syndrome	0.000159	0.000271	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000158	0.00027	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IRS1—polycystic ovary syndrome	0.000158	0.00027	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TAB1—polycystic ovary syndrome	0.000158	0.00027	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—polycystic ovary syndrome	0.000158	0.000269	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000157	0.000268	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PRL—polycystic ovary syndrome	0.000157	0.000267	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000154	0.000264	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TCF7L2—polycystic ovary syndrome	0.000154	0.000263	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000153	0.000261	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT2—polycystic ovary syndrome	0.000153	0.000261	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SLC2A4—polycystic ovary syndrome	0.000152	0.000259	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—INS—polycystic ovary syndrome	0.000151	0.000258	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000151	0.000257	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.000149	0.000255	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000148	0.000253	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.000147	0.000251	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT2—polycystic ovary syndrome	0.000147	0.000251	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT2—polycystic ovary syndrome	0.000146	0.00025	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PRL—polycystic ovary syndrome	0.000145	0.000247	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000143	0.000244	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000141	0.000241	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SERPINE1—polycystic ovary syndrome	0.000139	0.000237	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—INSR—polycystic ovary syndrome	0.000135	0.00023	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—BCL2—polycystic ovary syndrome	0.000134	0.000228	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL18—polycystic ovary syndrome	0.000132	0.000225	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	0.000131	0.000224	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—polycystic ovary syndrome	0.000129	0.000221	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRG1—polycystic ovary syndrome	0.000129	0.00022	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000128	0.000219	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000127	0.000216	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000126	0.000215	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PGR—polycystic ovary syndrome	0.000125	0.000213	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—LEP—polycystic ovary syndrome	0.000124	0.000212	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—polycystic ovary syndrome	0.000121	0.000207	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NCOR1—polycystic ovary syndrome	0.000121	0.000207	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	0.00012	0.000205	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	0.00012	0.000205	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRG1—polycystic ovary syndrome	0.000119	0.000203	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000116	0.000198	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000116	0.000198	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	0.000112	0.00019	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	0.000111	0.00019	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000111	0.000189	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000111	0.000189	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CRP—polycystic ovary syndrome	0.00011	0.000188	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRS2—polycystic ovary syndrome	0.00011	0.000188	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000108	0.000184	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTHFR—polycystic ovary syndrome	0.000107	0.000183	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—POMC—polycystic ovary syndrome	0.000107	0.000182	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—INS—polycystic ovary syndrome	0.000106	0.000181	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000103	0.000175	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000103	0.000175	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000102	0.000174	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IRS2—polycystic ovary syndrome	0.000102	0.000174	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PRL—polycystic ovary syndrome	0.000101	0.000173	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.74e-05	0.000166	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRS1—polycystic ovary syndrome	9.63e-05	0.000164	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.61e-05	0.000164	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	9.49e-05	0.000162	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	9.49e-05	0.000162	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT2—polycystic ovary syndrome	8.92e-05	0.000152	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GNAS—polycystic ovary syndrome	8.91e-05	0.000152	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IRS1—polycystic ovary syndrome	8.89e-05	0.000152	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—INS—polycystic ovary syndrome	8.52e-05	0.000145	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NCOR1—polycystic ovary syndrome	8.49e-05	0.000145	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRG1—polycystic ovary syndrome	8.33e-05	0.000142	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT2—polycystic ovary syndrome	8.23e-05	0.00014	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	7.95e-05	0.000136	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SERPINE1—polycystic ovary syndrome	7.82e-05	0.000133	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2—polycystic ovary syndrome	7.79e-05	0.000133	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	7.54e-05	0.000129	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	7.19e-05	0.000123	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IRS2—polycystic ovary syndrome	7.13e-05	0.000122	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LEP—polycystic ovary syndrome	6.98e-05	0.000119	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—polycystic ovary syndrome	6.92e-05	0.000118	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.7e-05	0.000114	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—polycystic ovary syndrome	6.62e-05	0.000113	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	6.41e-05	0.000109	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IRS1—polycystic ovary syndrome	6.23e-05	0.000106	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	6.11e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—POMC—polycystic ovary syndrome	6e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—INS—polycystic ovary syndrome	5.96e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1—polycystic ovary syndrome	5.77e-05	9.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT2—polycystic ovary syndrome	5.76e-05	9.84e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	5.58e-05	9.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.48e-05	9.35e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	5.45e-05	9.3e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	5.28e-05	9.01e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	4.86e-05	8.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	4.7e-05	8.03e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—polycystic ovary syndrome	4.63e-05	7.91e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	4.53e-05	7.74e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	4.36e-05	7.43e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	4.3e-05	7.34e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	4.06e-05	6.93e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—polycystic ovary syndrome	4.03e-05	6.88e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	4e-05	6.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.77e-05	6.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—polycystic ovary syndrome	3.72e-05	6.35e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TH—polycystic ovary syndrome	3.46e-05	5.91e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	3.37e-05	5.75e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	3.17e-05	5.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.83e-05	4.82e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.69e-05	4.59e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—polycystic ovary syndrome	2.61e-05	4.45e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.55e-05	4.35e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	2.38e-05	4.06e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.93e-05	3.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.9e-05	3.25e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.89e-05	3.23e-05	CbGpPWpGaD
